Neurogene Q3 10-Q: $94.4M Nine-Month Loss, $359.7M Cash Into Q1 2029
NGNE sits 63% above its 52-week low of $15.93.
Summary
Neurogene's Q3 10-Q details a $94.4M nine-month net loss and $359.7M in cash and investments that fund operations into Q1 2029, with $86.2M still available under its ATM and a 548,000-share inducement plan increase.
Key Events · Earnings and Guidance · NGNE
-
Q3 Loss Widens on Trial and CMC Spend
Net loss was $29.0M for the quarter and $94.4M for nine months, versus $20.95M and $65.6M a year earlier; R&D rose to $23.5M from $17.2M on Embolden trial costs and PPQ manufacturing runs.
-
Cash Funds Operations Into Q1 2029
Cash, cash equivalents and short-term investments totaled $359.7M at September 30, 2026, after $134.9M net from the July 2026 offering and $31.8M net from ATM sales.
-
ATM Leaves $86.2M of Overhang
889,054 shares were sold under the $150.0M Leerink Sales Agreement in the first nine months for $31.8M net; $86.2M remains available for future sales.
-
Inducement Plan Raised by 548,000 Shares
The board approved an increase to the 2025 Inducement Plan's share pool to 1,048,000 shares, effective August 13, 2026.
Analysis · NGNE · Life Sciences
Spending is ramping as Neurogene funds the Embolden registrational trial and process validation for NGN-401, per the full quarterly report behind this morning's 8-K. R&D rose to $23.5M in the quarter from $17.2M a year ago, and the nine-month net loss widened to $94.4M from $65.6M. The balance sheet is the offset: $359.7M of cash and short-term investments after the July offering and ATM sales, enough to fund operations into the first quarter of 2029, past the second-half 2027 Embolden topline. Dilution is the cost — shares outstanding grew to 20.7M from 15.5M at year-end, and $86.2M remains available under the ATM, a standing overhang. The only new governance item is a 548,000-share increase to the 2025 Inducement Plan.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NGNE was trading at $26.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $520.3M. The 52-week trading range was $15.93 to $43.66. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.